Improvement in the bioavailability of poorly absorbed glycyrrhizin via various non-vascular administration routes in rats

International Journal of Pharmaceutics

Volumn 265, Issue 1-2, 2003, Pages 95-102

  Sasaki, Kazuhiro ^a   Yonebayashi, Shingo ^a   Yoshida, Motoyuki ^a   Shimizu, Kenji ^a   Aotsuka, Tomaji ^a   Takayama, Kozo ^b  

^a Grelan Pharmaceutical Co   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Absorption enhancer; Fatty acids; Glycyrrhizin; Sodium caprate

Indexed keywords

DECANOATE SODIUM; FATTY ACID; GLYCYRRHIZATE DIPOTASSIUM; GLYCYRRHIZIC ACID DERIVATIVE; LAURATE SODIUM; OCTANOIC ACID; OLEATE SODIUM; SODIUM DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG PENETRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0141644230     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00407-1     Document Type: Article

References (23)

1. Amagaya S., Sugushita E., Ogihara Y., Ogawa S., Okada K., Aizawa T. Comparative studies of the stereo isomers of glycyrrhetinic acid on anti-inflammatory activities. J. Pharmacobiodyn. 7:1984;927-928.
2. Hattori M., Sakamoto T., Yamagishi T., Sakamoto K., Konishi K., Kobashi K., Namba T. Metabolism of glycyrrhizin by human intestinal flora. II: Isolation and characterization of human intestinal bacteria capable of destabilization glycyrrhizin an related compound. Chem. Pharm. Bull. 33:1985;210-217.
3. Hussain A., Hirai S., Bawarsgi R. Nasal absorption of propranolol from different dosage forms by rats and dog. J. Pharm. Sci. 69:1981;1411-1433.
4. Ichikawa T., Ishida T., Sakiya S., Sawada Y., Hanano M. Billiary excretion and enterohepatic cycling of glycyrrhizin in rats. J. Pharm. Sci. 75:1986;672-675.
5. Iino S., Tango T., Matsushima T., Toda G., Miyake K., Hino K., Kumada H., Yasuda K., Kuroki T., Hirayama C., Suzuki H. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol. Res. 19:2001;31-40.
6. Imai T., Sakai M., Ohtake H., Azuma H., Higashi Y., Otagiri M. In vitro and in vivo evaluation of the enhancing activity of glycyrrhizin on the intestinal absorption of drugs. Pharm. Res. 16:1999;80-86.
7. Lindmark T., Soderhoim J.D., Olaison G., Alvan G., Ocklind G., Artarsson P. Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm. Res. 14:1997;930-935.
8. Nakano N., Kato H., Suzuki H., Nakao K., Yano S., Kanaoka M. Enzyme immunoassay for glycyrrhetic acid and glycyrrhizin. Jpn. Pharmacol. Ther. 8:1980;4171-4174.
9. Nishihata T., Rytting J.H., Higuchi T. The effect of salicylate on the rectal absorption of lidocanin, L-Dopa and cefmetazole in rats. J. Pharm. Sci. 71:1982;869-872.
10. Sakai M., Imai I., Ohtake H., Azuma H., Otagiri M. Effect of absorption enhancers on the transport of model compounds in Caco-2 cell monolayers: assessment by confocal laser scanning microscopy. J. Pham. Sci. 86:1997;779-785.
11. Sekine M., Terashima H., Sasahara K., Nishimura K., Okada R., Awazu S. Improvement of bioavailability of poorly absorbed drugs. II. Effect of medium chain glyceride base on the intestinal absorption of cefmetazole sodium in rats and dogs. J. Pharm. Sci. 86:1997;779-785.
12. Shima M., Yohdoh K., Yamaguchi M., Yukitaka K., Adachi S., Matsuno R. Effect of medium-chain fatty acids and their acylglycerols on the transport of penicillin V across Caco-2 cell monolayers. Biosci. Biotech. Biochem. 61:1997;1150-1155.
13. Sutton S.C., LeCluyse E.L., Cammack L., Fix J.A. Enhanced bioavailability of cefoxitin using palmitoyl L-carnitine. I. Enhancer activity in different intestinal regions. Pharm. Res. 9:1992;191-194.
14. Takahashi K., Murakami T., Kamata K., Yumoto R., Higashi Y., Yata N. Pharmacokinetic analysis of absorption enhancing action of decanoic acid derivatives in rats. Pharm. Res. 11:1994;388-392.
15. Tanaka M., Takahashi M., Kuwahara E., Koyama O., Ohkubo K., Yotsuyanagi T. Effect of glycyrrhizinate on dissolution behavior and rectal absorption of amphotericin B in rabbits. Chem. Pharm. Bull. 40:1992;1559-1562.
16. Terasawa K., Bandoh M., Tosa H., Hirate J. Disposition of glycyrrhetic acid and its glycosides in healthy subjects and patients with pseudoaldosteronism. J. Pharmacobiodyn. 9:1986;95-100.
17. Tomita M., Shiga M., Hayashi M., Awazu S. Enhancement of colonic absorption by the paracellular permeation route. Pharm. Res. 5:1988a;341-346.
18. Tomita M., Hayashi M., Horie T., Ishizawa T., Awazu S. Enhancement of colonic absorption by the transcellular permeation route. Pharm. Res. 5:1988b;786-789.
19. Van Rossum T.G.J., Vult A.G., De Man R.A., Brouwer J.T., Schalm S.W. Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol. Ther. 12:1998;199-205.
20. Wang Z., Okamoto M., Kurosaki Y., Nakayama T., Kimura T. Pharmacokinetics of glycyrrhizin in rats with D-galactosamine-induced hepatic disease. Biol. Pharm. Bull. 19:1996;901-904.
21. Yamamoto A., Tanaka H., Okumura S., Shinsako K., Ito M., Yamashita M., Okada N., Fujita T., Muranishi S. Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane. Biol. Pharm. Bull. 24:2001;385-389.
22. Yano U., Suzuki H., Kumada H., Shimizu M., Hayashi N., Tango T. Evaluation of effect of Glycyron Tab. No.2 in the treatment of chronic hepatitis - study of double blind test. Rinshou Kenkyu. 66:1989;253-268.
23. Yoshitomi H., Nishihata T., Frederick G., Dillsaver M., Higuchi T. Effect of triglyceride on small intestinal absorption of cefoxitin in rats. J. Pharm. Pharmacol. 39:1987;887-891.